Different efficacies of neutralizing antibodies and antiviral drugs on SARS-CoV-2 Omicron subvariants, BA.1 and BA.2

被引：20

作者：

Ohashi, Hirofumi ^{[1
]}

Hishiki, Takayuki ^{[1
]}

Akazawa, Daisuke ^{[1
]}

Kim, Kwang Su ^{[2
,3
]}

Woo, Joohyeon ^{[2
]}

Shionoya, Kaho ^{[4
,5
]}

Tsuchimoto, Kana ^{[1
]}

Iwanami, Shoya ^{[2
]}

Moriyama, Saya ^{[1
]}

Kinoshita, Hitomi ^{[6
]}

Yamada, Souichi ^{[6
]}

Kuroda, Yudai ^{[7
]}

Yamamoto, Tsukasa ^{[7
]}

Kishida, Noriko ^{[8
]}

Watanabe, Shinji ^{[8
]}

Hasegawa, Hideki ^{[6
,8
]}

Suzuki, Tadaki ^{[9
]}

Maeda, Ken ^{[7
]}

Fukushi, Shuetsu ^{[6
]}

Takahashi, Yoshimasa ^{[1
]}

Iwami, Shingo ^{[2
,10
,11
,12
,13
,14
]}

Watashi, Koichi ^{[1
,4
,5
]}

机构：

[1] Natl Inst Infect Dis, Res Ctr Drug & Vaccine Dev, Tokyo 1628640, Japan

[2] Nagoya Univ, Grad Sch Sci, Div Biol Sci, Interdisciplinary Biol Lab iBLab, Nagoya, Aichi, Japan

[3] Pukyong Natl Univ, Dept Sci Syst Simulat, Busan, South Korea

[4] Natl Inst Infect Dis, Dept Virol 2, Tokyo 1628640, Japan

[5] Tokyo Univ Sci, Dept Appl Biol Sci, Noda, Chiba 2788510, Japan

[6] Natl Inst Infect Dis, Dept Virol 1, Tokyo 1628640, Japan

[7] Natl Inst Infect Dis, Dept Vet Sci, Tokyo 1628640, Japan

[8] Natl Inst Infect Dis, Ctr Influenza & Resp Virus Res, Tokyo 2080011, Japan

[9] Natl Inst Infect Dis, Dept Pathol, Tokyo 1628640, Japan

[10] Kyushu Univ, Inst Math Ind, Fukuoka, Japan

[11] Kyoto Univ, Inst Adv Study Human Biol ASHBi, Kyoto, Japan

[12] RIKEN, Interdisciplinary Theoret & Math Sci Program iTHE, Saitama, Japan

[13] Japanese Fdn Canc Res JFCR, NEXT Ganken Program, Tokyo, Japan

[14] Sci Groove Inc, Fukuoka 8100041, Japan

来源：

ANTIVIRAL RESEARCH | 2022年 / 205卷

关键词：

SARS-CoV-2; Omicron; BA.2; BA.1; Casirivimab; Imdevimab; Sotrovimab; Molnupiravir; Nirmatrelvir; Antiviral;

D O I：

10.1016/j.antiviral.2022.105372

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron subvariant BA.2 has spread in many countries, replacing the earlier Omicron subvariant BA.1 and other variants. Here, using a cell culture infection assay, we quantified the intrinsic sensitivity of BA.2 and BA.1 compared with other variants of concern, Alpha, Gamma, and Delta, to five approved-neutralizing antibodies and antiviral drugs. Our assay revealed the diverse sensitivities of these variants to antibodies, including the loss of response of both BA.1 and BA.2 to casirivimab and of BA.1 to imdevimab. In contrast, EIDD-1931 and nirmatrelvir showed a more conserved activities to these variants. The viral response profile combined with mathematical analysis estimated differences in antiviral effects among variants in the clinical concentrations. These analyses provide essential evidence that gives insight into variant emergence's impact on choosing optimal drug treatment.

引用

页数：4

共 17 条

[11] Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs [J].

Shen, Lin ;

Peterson, Susan ;

Sedaghat, Ahmad R. ;

McMahon, Moira A. ;

Callender, Marc ;

Zhang, Haili ;

Zhou, Yan ;

Pitt, Eleanor ;

Anderson, Karen S. ;

Acosta, Edward P. ;

Siliciano, Robert F. .

NATURE MEDICINE, 2008, 14 (07) :762-766

[12] Efficacy of Antibodies and Antiviral Drugs against Covid-19 Omicron Variant [J].

Takashita, Emi ;

Kinoshita, Noriko ;

Yamayoshi, Seiya ;

Sakai-Tagawa, Yuko ;

Fujisaki, Seiichiro ;

Ito, Mutsumi ;

Iwatsuki-Horimoto, Kiyoko ;

Chiba, Shiho ;

Halfmann, Peter ;

Nagai, Hiroyuki ;

Saito, Makoto ;

Adachi, Eisuke ;

Sullivan, David ;

Pekosz, Andrew ;

Watanabe, Shinji ;

Maeda, Kenji ;

Imai, Masaki ;

Yotsuyanagi, Hiroshi ;

Mitsuya, Hiroaki ;

Ohmagari, Norio ;

Takeda, Makoto ;

Hasegawa, Hideki ;

Kawaoka, Yoshihiro .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (10) :995-998

[13]

UK Health Security Agency (UKSH), 2022, 35 UKSH

[14] An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies [J].

VanBlargan, Laura A. ;

Errico, John M. ;

Halfmann, Peter J. ;

Zost, Seth J. ;

Crowe, James E., Jr. ;

Purcell, Lisa A. ;

Kawaoka, Yoshihiro ;

Corti, Davide ;

Fremont, Daved H. ;

Diamond, Michael S. .

NATURE MEDICINE, 2022, 28 (03) :490-+

[15] Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern [J].

Vangeel, Laura ;

Chiu, Winston ;

De Jonghe, Steven ;

Maes, Piet ;

Slechten, Bram ;

Raymenants, Joren ;

Andre, Emmanuel ;

Leyssen, Pieter ;

Neyts, Johan ;

Jochmans, Dirk .

ANTIVIRAL RESEARCH, 2022, 198

[16]

Viana M., 2022, NATURE, V2, P10, DOI DOI 10.1038/S41586-022-04411-Y

[17]

WHO, 2021, Nature

← 1 2 →